RxDoctor Payments Data

Robert Baskin, MD

Family Medicine · Plant City, FLNPI 1841252061

Payments from drug & device makers

$417in general payments, 2019–2025

Across 17 payments — averaging $24.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$114
  • AstraZeneca$82
  • GSK$53
  • Amgen$40
  • Teva Pharmaceuticals USA, Inc.$25
  • Novo Nordisk$24
  • plus $79 from 4 others

What the payments were for

  • Food & beverage$417100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$417 in reported general payments places this provider in the 45th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$41,492
Medicare patients
147
Services billed
527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban724$210,665
IngrezzaValbenazine Tosylate11$86,363
JardianceEmpagliflozin166$55,854
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog220$24,764
XareltoRivaroxaban57$23,726
XifaxanRifaximin15$18,496
TradjentaLinagliptin69$18,114
Memantine Hcl242$16,348
SantylCollagenase Clostridium Hist.46$14,865
Duloxetine Hcl207$12,917
Potassium Chloride237$11,749
Spiriva HandihalerTiotropium Bromide19$11,262
Fluticasone-SalmeterolFluticasone Propion/Salmeterol73$11,147
Combivent RespimatIpratropium/Albuterol Sulfate20$10,364
EntrestoSacubitril/Valsartan31$10,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$53$15,52628 claims
AstraZenecaBreztri Aerosphere, Symbicort$82$13,23335 claims
AbbVieLinzess$22$7,81912 claims
Novo NordiskNovolog$24$4,30254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Plant City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →